Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. ...
Faeth Therapeutics, Inc. (NASDAQ: FTH) is a U.S.-based, clinical-stage biotechnology company working to develop and advance novel treatments for patients with devastating forms of cancer. The company’s purpose is to improve patient lives by translating cancer biology into practical therapies, with an emphasis on multi-pathway targeting rather than single-agent approaches.
Business focus and strategy: Faeth’s core approach centers on identifying and disrupting key mechanisms cancer cells use to grow and survive. The provided materials highlight a lead program, PIKTOR, described as an investigational all-oral combination therapy designed to target the PI3K/AKT/mTOR pathway—an important signaling axis frequently implicated in oncogenesis and resistance. By concentrating on this pathway with a combination regimen, Faeth aims to improve clinical outcomes by simultaneously impacting interconnected nodes of tumor signaling.
Products and pipeline orientation: As a clinical-stage biotech, Faeth’s “product” is best understood as its clinical development programs and regimen candidates advancing through study phases. PIKTOR represents the company’s most visible lead effort, and the overall portfolio is aligned to the company’s broader theme of targeting tumor metabolism and critical oncogenic pathways.
Services and commercialization model: Faeth primarily operates as an R&D and development company rather than a provider of routine services or already-commercial products. Its work is typically structured around preclinical research, IND/enabling studies (where applicable), clinical trial design and execution, biomarker strategy, and progression of candidates based on emerging safety and efficacy data. Future commercialization—if successful—would likely involve partnered or direct commercialization of specific therapies, but near-term value is driven by trial progress and regulatory milestones.
Costs, BOM, and financial profile (practical view): Like many early-to-mid stage biotechs, Faeth’s economics are generally dominated by R&D and clinical trial execution costs (personnel, trial operations, laboratory/assay work, regulatory activity, and manufacturing/quality systems). While the provided financial snapshot includes valuation and margin-related metrics, these figures are not reliable indicators of steady-state profitability because biotech companies often invest heavily before generating sustainable revenue. In this context, key “cost drivers” are clinical timelines and program risk: trial enrollment, operational burn rate, and the ability to secure sufficient capital.
Key people: Anand Parikh serves as CEO and is identified as a founder/co-founder. The company was co-founded in 2019 alongside scientific leadership including Oliver Maddocks, PhD, and well-known cancer biologists such as Dr. Lewis Cantley, PhD—reflecting a foundation in oncology expertise.
Wishes/near-term priorities: For companies like Faeth, the near-term objectives typically include generating compelling clinical data for lead programs (e.g., PIKTOR), demonstrating tolerability and meaningful efficacy, validating biomarkers, and maintaining financial runway to continue development through subsequent study stages.
BYD Company LimitedHKEx:1211Mercedes-Benz Group AGXETRA:MBGMAN Truck & Bus SE (a TRATON SE brand)XETRA:8TRAScania AB (a TRATON SE brand)XETRA:8TRAVolvo Group (AB Volvo)STO:VOLV-BMarcopolo S.A.BOVESPA:POMO4Sasol LimitedJSE:SOLEngen Petroleum (Vivo Energy / Vitol)Bridgestone CorporationTSE:5108The Goodyear Tire & Rubber CompanyNASDAQ:GTContinental AGXETRA:CONTRATON SEXETRA:8TRAVolkswagen AGXETRA:VOWContemporary Amperex Technology Co., Limited (CATL)SHE:300750Multimech (Pty) Ltd
Downstream
9
Commuting Public (Cape Town Metro)Western Cape Government (Dept. of Transport & Public Works)School Transport Contracts (Various Schools in Western Cape)Tour Operators and Corporate Travel ClientsAlpine Truck and Bus (Pty) Ltd (51% owned subsidiary)Frontier Tyres (wholly owned subsidiary)Sibanye Bus ServicesTable Bay Area Rapid Transit (TBRT) / MyCiTiN2 Express (Pty) Ltd
Proxies
4
Hosken Consolidated Investments LimitedJSE:HCIZeda Limited (formerly Car Rental / Transport peer)JSE:ZEDFirstGroup plcLSE:FGPNational Express Group PLCLSE:NEX
